This site is intended for Great Britain healthcare professionals only 

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Menu

Close

AboutAboutHow Cibinqo worksIntroducing CibinqoMOA OverviewPatient ProfilesPatient Profiles OverviewPatient Profile 1Patient Profile 2Patient Profile 3Patient Profile 4EfficacyEfficacyClinical EfficacyStudy OverviewJADE COMPAREJADE MONOJADE REGIMENJADE TEENJADE EXTENDSafety
Safety
 
Safety
 
Safety Guidance
DosingDosingDosingOral once-daily dosingPractical ConsiderationsSupport & ResourcesSupport & ResourcesHCP ResourcesMedicine Evidence InformationPatient ResourcesVideos
Materials

Information on how to access Cibinqo® (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

Oral once-daily dosingStarting patients on CibinqoAnchor1For patients aged 12 years and older with moderate-to-severe atopic dermatitis who are candidates for systemic therapyAnchor

Cibinqo 200 mg and 100 mg is a once-daily oral treatment

  • For most patients, particularly those with severe disease, 200 mg is the recommended starting dose
  • ​​​​​​​100 mg is the recommended starting dose for patients aged ≥65 years, for adolescents aged 12–17 years, and for those who have risk factors for developing an adverse reaction to Cibinqo or who are less likely to tolerate any adverse reactions

The dose may be decreased or increased based on tolerability and efficacy. ​​​​​​​

  • ​​​​​​​Dose reduction can be considered after disease control is achieved in patients receiving 200 mg. Some patients may experience a disease flare after dose reduction. A higher risk of disease flare after dose reduction is associated with history of receiving systemic treatments for atopic dermatitis and extensive disease involving >50% of body surface area (BSA).

Cibinqo can be used with or without medicated topical therapies for atopic dermatitis

  • Discontinuation of treatment should be considered in patients who show no evidence of therapeutic benefit after 12 weeks.
  • Some patients with initial partial response may subsequently improve with continued treatment beyond 12 weeks

Cibinqo can be taken with or without food at approximately the same time each day

  • Taking Cibinqo with food may ease nausea if this is experienced by patients
  • Tablets should be swallowed whole with water and should not be split, crushed or chewed

image

Cibinqo 200 mg and 100 mg is a once-daily oral treatment

  • For most patients, particularly those with severe disease, 200 mg is the recommended starting dose
  • ​​​​​​​100 mg is the recommended starting dose for patients aged ≥65 years, for adolescents aged 12–17 years, and for those who have risk factors for developing an adverse reaction to Cibinqo or who are less likely to tolerate any adverse reactions
image​​​​​​​

The dose may be decreased or increased based on tolerability and efficacy. 

  • Dose reduction can be considered after disease control is achieved in patients receiving 200 mg. Some patients may experience a disease flare after dose reduction. A higher risk of disease flare after dose reduction is associated with history of receiving systemic treatments for atopic dermatitis and extensive disease involving >50% of body surface area (BSA).
image​​​​​​​

Cibinqo can be used with or without medicated topical therapies for atopic dermatitis

  • ​​​​​​​Discontinuation of treatment should be considered in patients who show no evidence of therapeutic benefit after 12 weeks.
  • Some patients with initial partial response may subsequently improve with continued treatment beyond 12 weeks
image​​​​​​​

Cibinqo can be taken with or without food at approximately the same time each day

  • Taking Cibinqo with food may ease nausea if this is experienced by patients
  • Tablets should be swallowed whole with water and should not be split, crushed or chewed
• Treatment should not be initiated in patients with a platelet count <150 x 103/mm3, an absolute lymphocyte count (ALC) <0.5 x 103/mm3, an absolute neutrophil count (ANC) <1 x 103/mm3, or a haemoglobin value <8 g/dL

• 50 mg dose is available for dose adjustments in special populations, e.g. moderate to severe renal impairment or in case of drug–drug interactions. See the full Summary of Product Characteristics for specific dose adjustment instructions. The 50 mg dose was not studied in clinical trials

​​​​​​​PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION
Contraindications1
  • Hypersensitivity to the active substance or to any of the excipients listed in the Summary of Product Characteristics
  • Active serious systemic infections, including tuberculosis (TB)
  • Severe hepatic impairment
  • Pregnancy
    • There are no or limited amount of data on the use of abrocitinib in pregnant women. Studies in animals have shown reproductive toxicity. Abrocitinib has been shown to cause skeletal variations in the foetuses of pregnant rats and rabbits and to affect parturition and peri/postnatal development in rats. Cibinqo is contraindicated during pregnancy
  • Breastfeeding
    • There are no data on the presence of Cibinqo in human milk, the effects on the breast-fed infant, or the effects on milk production. Cibinqo was secreted in milk of lactating rats. A risk to newborns/infants cannot be excluded and Cibinqo is contraindicated during breastfeeding
Cibinqo in special populations1Renal impairment
Mild (eGFR 60 to <90 mL/min) Moderate (eGFR 30 to <60 mL/min) Severe (eGFR <30 mL/min)
No dose adjustment required The recommended dose of Cibinqo should be reduced by half to 100 mg or 50 mg once daily 50 mg once daily is the recommended starting dose. The maximum daily dose is 100 mg

Cibinqo has not been studied in patients with end-stage renal disease (ESRD) on renal replacement therapy.​​​​​​​

Hepatic impairment
Scroll left to view table
Mild Moderate Severe
No dose adjustment required No dose adjustment required Not studied, must not be used
Elderly

The recommended starting dose for patients ≥65 years of age is 100 mg once daily.

Paediatric

The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily. The safety and efficacy of Cibinqo in children under 12 years of age have not yet been established. No data are available.

Women of childbearing potential 

Women of reproductive potential should be advised to use effective contraception during treatment and for 1 month following the final dose of Cibinqo. Pregnancy planning and prevention for females of reproductive potential should be encouraged.

PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION​​​​​​​.Cibinqo – Interactions with other medicationsDrug–drug interactions may require dose modifications of Cibinqo
Scroll left to view table
Interaction Examples Clinical impact Action
Strong CYP2C19 inhibitors fluvoxamine, fluconazole, fluoxetine and ticlopidine Increased exposure to Cibinqo moiety Reduce dose of Cibinqo by half to 100 mg or 50 mg once daily
Strong CYP2C19 or CYP2C9 inducers rifampicin, apalutamide, efavirenz, enzalutamide, phenytoin Decreased exposure to Cibinqo active moiety and may result in loss of or reduced clinical response Concomitant use of Cibinqo is not recommended
MOA inhibitors selegiline, isocarboxazid Not studied in humans. Clinical impact not known Caution should be exercised for concomitant use
Potential for Cibinqo to affect other medications

No clinically significant effects of Cibinqo were observed in drug interaction studies with oral contraceptives (e.g. ethinyl oestradiol/levonorgestrel).

​​​​​​​In vitro, Cibinqo is an inhibitor of P-gp. Co-administration of dabigatran etexilate (a P-gp substrate), with a single dose of Cibinqo 200 mg increased dabigatran AUCinf and Cmax by approximately 53% and 40%, respectively, compared with administration alone. Caution should be exercised for concomitant use of Cibinqo with dabigatran.

​​​​​​​The effect of Cibinqo on pharmacokinetics of other P-gp substrates has not been evaluated. Caution should be exercised as the levels of P-gp substrates with a narrow therapeutic index, such as digoxin and ciclosporin, may increase.
PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION​​​​​​​.
 
Explore morePractical considerations

Learn more about monitoring patients on Cibinqo.

View requirementsLoading
Patient resources

Access resources to help you support your patients on Cibinqo.

View resourcesLoading

CYP=cytochrome P; eGFR=estimated glomerular filtration rate; MOA=monoamine oxidase; P-gp=P glycoprotein.

Prescribing information:
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 200 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 100 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 50 mg film-coated tablets.

References:

Cibinqo (abrocitinib) Summary of Product Characteristics.
PP-CIB-GBR-0068. October 2021

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.

Dosing

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2021 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-PFE-GBR-3849. November 2021

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?

You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes No
You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​